EGFR and non-small cell lung carcinoma: Erlotinib, the first approved target drug for NSCLC, is a reversible tyrosine kinase inhibitor that targets the epidermal growth factor receptor and can significantly improve the survival of LUAD patients (Faehling et al., 2018).